• Advise patients that psychiatric symptoms (paranoia, hostility, mania, depressive, suicidal) and cognitive symptoms (confusion, memory problems, speech disorder) may occur during treatment with PRIALT.
• Caution patients against engaging in hazardous activity requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle during treatment with PRIALT.
• Caution patients about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when PRIALT is administered with such agents because of the potentially additive effects.
• Advise patients to contact a physician if the patient experiences new or worsening muscle pain, soreness, weakness with or without darkened urine.
• Instruct patients and their caregivers to contact a physician immediately if the patient has any of the following
  • A change in mental status (e.g., lethargy, confusion, disorientation, decreased alertness)
  • A change in mood, perception (hallucinations, including unusual tactile sensations in the oral cavity)
  • Symptoms of depression or suicidal ideation
  • Nausea, vomiting, seizures, fever, headache, and/or stiff neck, as these may be symptoms of developing meningitis
  • Decreased level of consciousness, unresponsiveness or stupor
  • New muscular symptoms (e.g., muscle cramps, myalgias)
  • Withdrawal symptoms (e.g., nausea, insomnia, flu-like symptoms) as a result of abruptly discontinuing opioid therapy
  • Development of serious skin reaction (e.g., bullous dermatitis, skin ulcers, skin exfoliation)

For use only in the Medtronic SynchroMed® II Infusion System and CADD-Micro Ambulatory Infusion Pump.

Last reviewed on RxList: 9/12/2011
This monograph has been modified to include the generic and brand name in many instances.